A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.
Browsing: Amyotrophic lateral sclerosis
After careful evaluation of the ‘Right to Try ‘Act, BrainStorm have announced that it will not make NurOwn® available under this legislation at this time.
Researchers have identified genes in the human genome that could modify the severity of amyotrophic lateral sclerosis and frontotemporal dementia.
Disturbance to nuclear transport caused by protein aggregation has been implicated in the pathology of ALS and FTD.
As we begin a new year on Neuro Central, we’re taking this opportunity to look back at some of the highlights across neuroscience and neurology in 2017.
Discover more about how advances in amyotrophic lateral sclerosis research are influencing approaches to patient care in this review from Neurodegenerative Disease Management
Researchers from the University of Missouri have discovered an enzyme pathway that may present a potential therapeutic target for ALS and, possibly, other neurological diseases including stroke.
The California Institute for Regenerative Medicine (CIRM) announces that it is investing $15.9 million in a therapy to tackle ALS.
Researchers discover that the drug, pyrimethamine, may reduce disease progression in patients with inherited amyotrophic lateral sclerosis (ALS).
Participants in the top 25% for estimated annual mercury intake had a twofold higher risk of developing amyotrophic lateral sclerosis.